160 related articles for article (PubMed ID: 13680379)
1. Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling.
Buerger C; Groner B
J Cancer Res Clin Oncol; 2003 Dec; 129(12):669-75. PubMed ID: 13680379
[TBL] [Abstract][Full Text] [Related]
2. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells.
Nagel-Wolfrum K; Buerger C; Wittig I; Butz K; Hoppe-Seyler F; Groner B
Mol Cancer Res; 2004 Mar; 2(3):170-82. PubMed ID: 15037656
[TBL] [Abstract][Full Text] [Related]
3. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
Kunz C; Borghouts C; Buerger C; Groner B
Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
[TBL] [Abstract][Full Text] [Related]
4. Validating Stat3 in cancer therapy.
Darnell JE
Nat Med; 2005 Jun; 11(6):595-6. PubMed ID: 15937466
[No Abstract] [Full Text] [Related]
5. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
6. Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition.
Borghouts C; Kunz C; Delis N; Groner B
Mol Cancer Res; 2008 Feb; 6(2):267-81. PubMed ID: 18314488
[TBL] [Abstract][Full Text] [Related]
7. Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells.
Mern DS; Hoppe-Seyler K; Hoppe-Seyler F; Hasskarl J; Burwinkel B
Breast Cancer Res Treat; 2010 Dec; 124(3):623-33. PubMed ID: 20191379
[TBL] [Abstract][Full Text] [Related]
8. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.
Zhang T; Ma J; Cao X
Biochem J; 2003 Dec; 376(Pt 2):457-64. PubMed ID: 14498832
[TBL] [Abstract][Full Text] [Related]
9. STAT proteins: novel molecular targets for cancer drug discovery.
Turkson J; Jove R
Oncogene; 2000 Dec; 19(56):6613-26. PubMed ID: 11426647
[TBL] [Abstract][Full Text] [Related]
10. Peptide aptamers: recent developments for cancer therapy.
Borghouts C; Kunz C; Groner B
Expert Opin Biol Ther; 2005 Jun; 5(6):783-97. PubMed ID: 15952909
[TBL] [Abstract][Full Text] [Related]
11. Druggable signaling proteins.
Sioud M; Leirdal M
Methods Mol Biol; 2007; 361():1-24. PubMed ID: 17172705
[TBL] [Abstract][Full Text] [Related]
12. Identification of a high-affinity phosphopeptide inhibitor of Stat3.
Ren Z; Cabell LA; Schaefer TS; McMurray JS
Bioorg Med Chem Lett; 2003 Feb; 13(4):633-6. PubMed ID: 12639546
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
Badache A; Hynes NE
Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
[TBL] [Abstract][Full Text] [Related]
14. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.
Song H; Wang R; Wang S; Lin J
Proc Natl Acad Sci U S A; 2005 Mar; 102(13):4700-5. PubMed ID: 15781862
[TBL] [Abstract][Full Text] [Related]
15. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells.
Nam S; Buettner R; Turkson J; Kim D; Cheng JQ; Muehlbeyer S; Hippe F; Vatter S; Merz KH; Eisenbrand G; Jove R
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):5998-6003. PubMed ID: 15837920
[TBL] [Abstract][Full Text] [Related]
16. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
17. Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors.
Groner B; Weber A; Mack L
Bioengineered; 2012; 3(6):320-5. PubMed ID: 22825353
[TBL] [Abstract][Full Text] [Related]
18. The zinc finger protein Gfi-1 can enhance STAT3 signaling by interacting with the STAT3 inhibitor PIAS3.
Rödel B; Tavassoli K; Karsunky H; Schmidt T; Bachmann M; Schaper F; Heinrich P; Shuai K; Elsässer HP; Möröy T
EMBO J; 2000 Nov; 19(21):5845-55. PubMed ID: 11060035
[TBL] [Abstract][Full Text] [Related]
19. The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells.
Nikitakis NG; Hamburger AW; Sauk JJ
Cancer Res; 2002 Feb; 62(4):1004-7. PubMed ID: 11861373
[TBL] [Abstract][Full Text] [Related]
20. Formation of autocrine loops in human cerebral meningioma tissue by leukemia inhibitor factor, interleukin-6, and oncostatin M: inhibition of meningioma cell growth in vitro by recombinant oncostatin M.
Schrell UM; Koch HU; Marschalek R; Schrauzer T; Anders M; Adams E; Fahlbusch R
J Neurosurg; 1998 Mar; 88(3):541-8. PubMed ID: 9488310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
